In vitro screening for drug repositioning

Journal of Biomolecular Screening

Volumn 20, Issue 2, 2015, Pages 167-179

  Wilkinson, Graeme F ^a   Pritchard, Kevin ^b  

^a ASTRAZENECA   (United Kingdom)

^b Kevin Pritchard Department   (United Kingdom)

Author keywords

in vitro; repositioning; review; screening

Indexed keywords

CENTRAL NERVOUS SYSTEM DISEASE; DRUG INDUSTRY; DRUG INFORMATION; DRUG REPOSITIONING; DRUG SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFORMATION SCIENCE; NEOPLASM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TROPICAL DISEASE; ANIMAL; BIOASSAY; BIOLOGY; DRUG DEVELOPMENT; PROCEDURES;

ANIMALS; BIOLOGICAL ASSAY; COMPUTATIONAL BIOLOGY; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG REPOSITIONING; HUMANS; IN VITRO TECHNIQUES;

EID: 84921487539     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057114563024     Document Type: Review

References (105)

1. Ashburn T. T., Thor K. B. Drug Repositioning: Identifying and Developing New Uses for Existing Drugs. Nat. Rev. Drug Disc. 2004 ; 3: 673-683
2. Barratt M. J., Frail D. F. Drug Repositioning: Bringing New Life to Shelved Assets and Existing Drugs. Wiley: Hoboken ; 2013 :
3. Allison M. NCATS Launches Drug Repurposing Program. Nature Biotechnology. 2012 ; 30: 571-572
4. Ekins S., Williams A. J. Finding Promiscuous Old Drugs for New Uses. Pharm. Res 28. 2011 ;: 1785-1791
5. Mullard A. Drug Repurposing Programmes Get Lift Off. Nat. Rev. Drug Disc. 2012 ; 11: 505-506
6. Osherovich L. AstraZeneca's Compound Interest. SciBX. 2012 ; 5 ( 1 ):
7. Hunter J., Stephens S. Is Open Innovation the Way Forward for Big Pharma?. Nat. Rev. Drug Disc. 2010 ; 9: 87-88
8. Simpson P. B., Reichman M. Opening the Lead Generation Toolbox. Nat. Rev. Drug Disc. 2014 ; 13: 3-4
9. Miller G. Is Pharma Running Out of Brainy Ideas?. Science. 2010 ; 329: 502-504
10. DiMasi J. A. Innovating by Developing New Uses of Already-Approved Drugs: Trends in the Marketing Approval of Supplemental Indications. Clin. Ther. 2013 ; 35: 808-818
11. Edwards B. S., Gouveia K., Oprea T. I., et al. The University of New Mexico Center for Molecular Discovery. Comb. Chem. High Throughput Screen. 2014 ; 17: 256-265
12. Li Y. Y., Jones S. J. Drug Repositioning for Personalized Medicine. Genome Med. 2012 ; 4: 27
13. Brenk R., Schipani A., James D., et al. Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases. Chem. Med. Chem. 2008 ; 3: 435-444
14. Mullard A. Partnering between Pharma Peers on the Rise. Nat. Rev. Drug Disc. 2011 ; 10: 561-562
15. Huang R., Southall N., Wang Y., et al. The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics. Sci. Transl. Med. 2011 ; 27: 80
16. Chong C. R., Chen X., Shi L., et al. A Clinical Drug Library Screen Identifies Astemizole as an Antimalarial Agent. Nat. Chem. Biol. 2006 ; 2: 415-416
17. Cavalla D. Predictive Methods in Drug Repurposing: Gold Mine or Just a Bigger Haystack?. Drug Discov. Today. 2013 ; 18: 523-532
18. Jin G., Wong S. T. C. Toward Better Drug Repositioning: Prioritizing and Integrating Existing Methods into Efficient Pipelines. Drug Disc. Today. 2014 ; 9: 637-644
19. Hurle M. R., Yang L., Xie Q., et al. Computational Drug Repositioning: From Data to Therapeutics. Clin. Pharmacol. Ther. 2013 ; 93: 335-341
20. Iorio F., Rittman T., Ge H., et al. Transcriptional Data: A New Gateway to Drug Repositioning?. Drug Discov. Today. 2013 ; 18: 350-357
21. Pan Y., Cheng T., Wang Y., et al. Pathway Analysis for Drug Repositioning Based on Public Database Mining. J. Chem. Inf. Model. 2014 ; 54: 407-418
22. Vazquez-Martin A., López-Bonetc E., Cufí S., et al. Repositioning Chloroquine and Metformin to Eliminate Cancer Stem Cell Traits in Pre-malignant Lesions. Drug Resist. Update. 2011 ; 14: 212-223
23. Sirota M., Dudley J. T., Kim J., et al. Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data. Sci. Transl. Med. 2011 ; 3 ( 96 ):
24. Dudley J. T., Sirota M., Shenoy M., et al. Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease. Sci. Transl. Med. 2011 ; 3 ( 96 ):
25. Hoehndorf R., Oellrich A., Rebholz-Schuhmann D., et al. Linking PharmGKB to Phenotype Studies and Animal Models of Disease for Drug Repurposing. Pac. Symp. Biocomput. 2012: 388-399
26. Reaume A. Drug Repurposing through Nonhypothesis Driven Phenotypic Screening. Drug Disc. Today. 2011 ; 8: 85-88
27. Saporito M. S., Lipinski C., Reaume A. Phenotypic In Vivo Screening to Identify New, Unpredicted Indications for Existing Drugs and Drug Candidates. Wiley: Hoboken ; 2012 :
28. Whalley K. Phenotypic Screening: Zebrafish Behavior in Profile. Nature Rev. Drug Disc. 2010 ; 9: 192-193
29. Zon L. I., Peterson R. T. In Vivo Drug Discovery in Zebrafish. Nat. Reviews Drug Disc. 2005 ; 4: 35-44
30. Kaletta T., Hengartner M. O. Finding Function in Novel Targets: C. elegans as a Model Organism. Nat. Rev. Drug Disc. 2006 ; 5: 387-399
31. McRae C. A., Peterson R. T. Zebrafish as a Platform for In Vivo Drug Discovery. Drug Disc. Today Dis. Mod. 2013 ; 10: e1 -e56
32. Burns C. G., Milan D. J., Grande E. J., et al. High-Throughput Assay for Small Molecules That Modulate Zebrafish Embryonic Heart Rate. Nat. Chem. Biol. 2005 ; 1: 263-264
33. Milan D. J., Peterson T. A., Ruskin J. N., et al. Drugs That Induce Repolarization Abnormalities Cause Bradycardia in Zebrafish. Circulation. 2003 ; 107: 1355-1358
34. Howe K., Clark M. D., Torroja C. F., et al. The Zebrafish Reference Genome Sequence and Its Relationship to the Human Genome. Nature. 2013 ; 496: 498-503
35. Binder V., Zon L. I. High Throughput In Vivo Phenotyping: The Zebrafish as Tool for Drug Discovery for Hematopoietic Stem Cells and Cancer. Drug Disc. Today Dis. Mod. 2013 ; 10: e17 -e22
36. Leung M. C. K., Williams P. L., Benedetto A., et al. Caenorhabditis elegans: An Emerging Model in Biomedical and Environmental Toxicology. Toxicol. Sci. 2008 ; 106: 5-28
37. Kwok T. C. Y., Ricker N., Fraser R., et al. A Small-Molecule Screen in C. elegans Yields a New Calcium Channel Antagonist. Nature. 2006 ; 441: 91-95
38. Antoshechkin I., Sternberg P. W. The Versatile Worm: Genetic and Genomic Resources for Caenorhabditis elegans Research. Nat. Rev. Genet. 2007 ; 8: 518-532
39. Rovira M., Huang W., Yusuff S., et al. Chemical Screen Identifies FDA Approved Drugs and Target Pathways That Induce Precocious Pancreatic Endocrine Differentiation. Proc. Natl. Acad. Sci. USA. 2011 ; 108: 19264-19269
40. Cousin M. A., Ebbert J. O., Wiinamaki A. R., et al. Larval Zebrafish Model for FDA-Approved Drug Repositioning for Tobacco Dependence Treatment. PLoS ONE. 2014 ; 9: e90467
41. Vlasits A. L., Simon J. A., Raible D. W., et al. Screen of FDA-Approved Drug Library Reveals Compounds That Protect Hair Cells from Aminoglycosides and Cisplatin. Hear. Res. 2012 ; 294: 153-165
42. Parsons M. J., Pisharath H., Yusuff S., et al. Notch-Responsive Cells Initiate the Secondary Transition in Larval Zebrafish Pancreas. Mech. Dev. 2009 ; 126: 898-912
43. Klee E. W., Schneider H., Clark K. J., et al. Zebrafish: A Model for the Study of Addiction Genetics. Hum. Genet. 2012 ; 131: 977-1008
44. Klee E. W., Ebbert J. O., Schneider H., et al. Zebrafish for the Study of the Biological Effects of Nicotine. Nicotine Tob. Res. 2011 ; 13: 301-312
45. Coombs S., Gorner P., Munz H. The Mechanosensory Lateral Line: Neurobiology and Evolution. Springer-Verlag: New York ; 1989 :
46. Nicolson T. The Genetics of Hearing and Balance in Zebrafish. Ann. Rev. Genet. 2005 ; 39: 9-22
47. Buckley C. E., Marguerie A., Roach A. G., et al. Drug Reprofiling Using Zebrafish Identifies Novel Compounds with Potential Promyelination Effects. Neuropharmacology. 2010 ; 59: 149-159
48. Ou H. C., Cunningham L. L., Francis S. P., et al. Identification of FDA-Approved Drugs and Bioactives That Protect Hair Cells in the Zebrafish (Danio rerio) Lateral Line and Mouse (Mus musculus) Utricle. J. Assoc. Res. Otolaryngol. 2009 ; 10: 191-203
49. Lublin A., Isoda F., Patel H., et al. FDA-Approved Drugs That Protect Mammalian Neurons from Glucose Toxicity Slow Aging Dependent on Cbp and Protect against Proteotoxicity. PLoS ONE. 2011 ; 6: e27762
50. Evason K., Huang C., Yamben I., et al. Anticonvulsant Medications Extend Worm Life-Span. Science. 2005 ; 307: 258-262
51. Working to Overcome the Burden of Neglected Tropical Diseases. WHO Press: Geneva ; 2010 :
52. Spangenberg T., Burrows J. N., Kowalczyk P., et al. The Open Access Malaria Box: A Drug Discovery Catalyst for Neglected Diseases. PLoS ONE. 2013 ; 8: e62906
53. Cheng F., Liu C., Jiang J., et al. Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference. PLoS Comput. Biol. 2012 ; 8: e1002503
54. Li Y. Y., An J., Jones S. J. A Computational Approach to Finding Novel Targets for Existing Drugs. PLoS Comput. Biol. 2011 ; 7: e1002139
55. Rosenthal P. J., Sijwali P. S., Singh A., et al. Cysteine Proteases of Malaria Parasites: Targets for Chemotherapy. Curr. Pharm. Des. 2002 ; 8: 1659-1672
56. Vermeire J. J., Lantz L. D., Caffrey C. R. Cure of Hookworm Infection with a Cysteine Protease Inhibitor. PLoS Negl. Trop. Dis. 2012 ; 6: e1680
57. Chen G. Z., Foster L., Bennett J. L. Antischistosomal Action of Mevinolin: Evidence That 3-Hydroxy-Methylglutaryl-Coenzyme a Reductase Activity in Schistosoma mansoni Is Vital for Parasite Survival. Naunyn. Schmiedebergs Arch. Pharmacol. 1990 ; 342: 477-482
58. Vandewaa E. A., Mills G., Chen G. Z., et al. Physiological Role of HMG-CoA Reductase in Regulating Egg Production by. Schistosoma mansoni. Am. J. Physiol. -Regul. Int. Comp. Physiol. 1989 ; 257: R618 -R625
59. Doerig C., Meijer L., Mottram J. C. Protein Kinases as Drug Targets in Parasitic Protozoa. Trends Parasitol. 2002 ; 18: 366-371
60. Urbaniak M. D., Mathieson T., Bantscheff M., et al. Chemical Proteomic Analysis Reveals the Drugability of the Kinome of. Trypanosoma brucei. ACS Chem. Biol. 2012 ; 7: 1858-1865
61. Gloeckner C., Garner A. L., Mersha F., et al. Repositioning of an Existing Drug for the Neglected Tropical Disease Onchocerciasis. Proc. Natl. Acad. Sci. USA. 2010 ; 107: 3424-3429
62. Abdulla M-H., Ruelas D. S., Wolff B., et al. Drug Discovery for Schistosomiasis: Hit and Lead Compounds Identified in a Library of Known Drugs by Medium-Throughput Phenotypic Screening. PLoS Negl. Trop. Dis. 2009 ; 3: e478
63. Nurse P. A Long Twentieth Century of the Cell Cycle, and Beyond. Cell. 2000 ; 100: 71-78
64. Viotti R., Vigliano C., Lococo B., et al. Side Effects of Benznidazole as a Treatment in Chronic Chagas Disease: Fears and Realities. Exp. Rev. Anti-infect. Ther. 2009 ; 7: 157-163
65. Debnath A., Ndao M., Reed S. L. Reprofiled Drug Targets Ancient Protozoans. Gut Microbes. 2013 ; 4: 66-71
66. Tejman-Yarden N., Miyamoto Y., Leitsch D., et al. A Reprofiled Drug, Auranofin, Is Effective against Metronidazole-Resistant Giardia lamblia. Antimicrob. Agents Chemother. 2013 ; 57: 2029-2035
67. Bromme D., Lacaille F. Cathepsin K Inhibitors for Osteoporosis and Potential Off-Target Effects. Exp. Opin. Invest. Drugs. 2009 ; 18: 585-600
68. Dent J. A., Davis M. W., Avery L. avr-15 Encodes a Chloride Channel Subunit That Mediates Inhibitory Glutamatergic Neurotransmission and Ivermectin Sensitivity. Caenorhabditis elegans. EMBO J. 1997 ; 16: 5867-5879
69. Geyer J., Gavrilova O., Petzinger E. Brain Penetration of Ivermectin and Selamectin in mdr1a,b P-glycoprotein-and bcrp-Deficient Knockout Mice. J. Vet. Pharmacol. Ther. 2009 ; 32: 87-96
70. Patel G., Karver C. E., Behera R., et al. Kinase Scaffold Repurposing for Neglected Disease Drug Discovery: Discovery of an Efficacious, Lapatanib-Derived Lead Compound for Trypanosomiasis. J. Med. Chem. 2013 ; 56: 3820-3832
71. Ochiana S. O., Pandarinath V., Wang Z., et al. The Human Aurora Kinase Inhibitor Danusertib Is a Lead Compound for Anti-trypanosomal Drug Discovery via Target Repurposing. Eur. J. Med. Chem. 2013 ; 62: 777-784
72. Carvalho T. G., Doerig C., Reininger L. Nima-and Aurora-Related Kinases of Malaria Parasites. Biochim. Biophys. Acta. 2013 ; 1834: 1336-1345
73. Hubsher G., Haider M., Okun M. S. Amantadine: The Journey from Fighting Flu to Treating Parkinson Disease. Neurology. 2012 ; 3: 1096-1099
74. Corbett A., Pickett J., Burns A., et al. Drug Repositioning for Alzheimer's Disease. Nat. Rev. Drug. Disc. 2012 ; 11: 833-846
75. Forette F., Seux M. L., Staessen J. A., et al. The Prevention of Dementia with Antihypertensive Treatment. Arch. Intern. Med. 2002 ; 162: 2046-2052
76. Paris D., Bachmeier C., Patel N., et al. Selective Antihypertensive Dihydropyridines Lower Ab Accumulation by Targeting Both the Production and Clearance of Ab across the Blood-Brain Barrier. Mol. Med. 2011 ; 17: 149-162
77. Hayes C. D., Dey D., Palavicini J. P., et al. Striking Reduction of Amyloid Plaque Burden in an Alzheimer's Mouse Model after Chronic Administration of Carmustine. BMC Med. 2013 ; 26: 81
78. MichaelJ.Fox Foundation. MJFF grants catalog 2013. https://www.michaeljfox.org/files/071414 (accessed Oct 23, 2014).
79. Fagan S. C. Drug Repurposing for Drug Development in Stroke. Pharmacotherapy. 2010 ; 30: 51S -54S
80. Hess D. C., Fagan S. Repurposing an Old Drug to Improve the Safety and Use of Tissue Plasminogen Activator for Acute Ischemic Stroke: Minocycline. Pharmacotherapy. 2010 ; 30 :
81. Amiri-Nikpour M. R., Nazarbaghi S., Hamdi-Holasou M., et al. An Open-Label Evaluator-Blinded Clinical Study of Minocycline Neuroprotection in Ischemic Stroke: Gender-Dependent Effect. Acta Neurol. Scand. 2014 ;:
82. Hornslien A. G., Sandset E. C., Bath P. M., et al. Effects of Candesartan in Acute Stroke on Cognitive Function and Quality of Life: Results from the Scandinavian Candesartan Acute Stroke Trial. Stroke. 2013 ; 44: 2022-2024
83. Jahchan N. S., Dudley J. T., Mazur P. K., et al. A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors. Cancer Discov. 2013 ; 3: 1364-1377
84. Pessetto Z. Y., Weir S. J., Sethi G., et al. Drug Repurposing for Gastrointestinal Stromal Tumor. Mol. Cancer Ther. 2013 ; 12: 1299-1309
85. Taylor D. J. Parallel Screening of FDA-Approved Antineoplastic Drugs for Identifying Sensitizers of TRAIL-Induced Apoptosis in Cancer Cells. BMC Cancer. 2011 ; 11: 470
86. Nygren P., Fryknäs M., Agerup B., et al. Repositioning of the Antihelmintic Drug Mebendazole for the Treatment for Colon Cancer. J. Cancer Res. Clin. Oncol. 2013 ; 139: 2133-2140
87. Platz E. A., Yegnasubramanian S., Liu J. O., et al. A Novel Two-Stage, Transdisciplinary Study Identifies Digoxin as a Possible Drug for Prostate Cancer Treatment. Cancer Discov. 2011 ; 1: 68-77
88. Jiang P., Mukthavavam R., Chao Y., et al. Novel Anti-glioblastoma Agents and Therapeutic Combinations Identified from a Collection of FDA Approved Drugs. J. Trans. Med. 2014 ; 12: 13
89. Wen P. Y., Kesari S. Malignant Gliomas in Adults. N. Engl. J. Med. 2008 ; 359: 492-507
90. Sharma A., Jacob A., Tandon M., et al. Orphan Drug: Development Trends and Strategies. J. Pharm. Bioallied Sci. 2010 ; 2: 290-299
91. National Cancer Institute. A Phase I Trial of Nelfinavir (Viracept) in Adults with Solid Tumors. ClinicalTrials.gov, NCT01445106.
92. Greenstone G. The Revival of Thalidomide: From Tragedy to Therapy. Brit. Columb. Med. J. 2011 ; 53: 230-233
93. Iyer C. G. S., Languillon J., Ramanujam K., et al. WHO Co-ordinated Short-Term Doubleblind Trial with Thalidomide in the Treatment of Acute Lepra Reactions in Male Lepromatous Patients. Bull. Wld. Hlth. Org. 1971 ; 45: 719-732
94. D'Amato R., Loughnan M. S., Flynn E., et al. Thalidomide Is an Inhibitor of Angiogenesis. Proc. Natl. Acad. Sci. USA. 1994 ; 91: 4082-4085
95. Singhal S., Mehta J., Desikan R., et al. Antitumor Activity of Thalidomide in Refractory Multiple Myeloma. New Engl. J. Med. 1999 ; 341: 1565-1571
96. Evans J. M. M., Donnelly L. A., Emslie-Smith A. M., et al. Metformin and the Reduced Risk of Cancer in Diabetic Patients. Brit. Med. J. 2005 ; 330: 1304-1305
97. Micic D., Cvijovic G., Trajkovic V., et al. Metformin: Its Emerging Role in Oncology. Hormones (Athens). 2011 ; 10: 5-15
98. Liu B., Fan Z., Edgerton S. M., et al. Metformin Induces Unique Biological and Molecular Responses in Triple Negative Breast Cancer Cells. Cell Cycle. 2009 ; 8: 2031-2040
99. Buzzai M., Jones R. G., Amaravadi R. K., et al. Systemic Treatment with the Antidiabetic Drug Metformin Selectively Impairs p53-Deficient Tumor Cell Growth. Cancer Res. 2007 ; 67: 6745-6752
100. Hirsch H. A., Iliopoulos D., Tsichlis P. N., et al. Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission. Cancer Res. 2009 ; 69: 7507-7511
101. Sardana D., Zhu C., Zhang M., et al. Drug Repositioning for Orphan Diseases. Brief. Bioinform. 2011 ; 12: 346-356
102. Xu K., Coté T. R. Database Identifies FDA-Approved Drugs with Potential to Be Repurposed for Treatment of Orphan Diseases. Brief. Bioinform. 2011 ; 12: 341-345
103. Van Herle K., Behne J. M., Van Herle A., et al. Integrative Continuum: Accelerating Therapeutic Advances in Rare Autoimmune Diseases. Ann. Rev. Pharmacol. Toxicol. 2012 ; 52: 523-547
104. Beaulieu C. L., Samuels M. E., Ekins S., et al. A Generalizable Pre-clinical Research Approach for Orphan Disease Therapy. Orphanet J Rare Dis. 2012 ; 15: 39
105. Lee H. S., Bae T., Lee J. H., et al. Rational Drug Repositioning Guided by an Integrated Pharmacological Network of Protein, Disease and Drug. BMC Syst. Biol. 2012 ; 6: 80